Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Maat Pharma SA

4RD:DUS

Maat Pharma SA

Actions
  • Price (EUR)6.34
  • Today's Change-0.52 / -7.58%
  • Shares traded--
  • 1 Year change-15.24%
  • Beta--
Data delayed at least 15 minutes, as of Jun 18 2024 07:11 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in EURView more

In 2023, cash reserves at Maat Pharma SA fell by 10.97m. Cash Flow from Financing totalled 8.14m or 365.39% of revenues. In addition the company used 18.67m for operations while cash used for investing totalled 440.00k.
Cash flow per share-1.66
Price/Cash flow per share--
Book value per share1.76
Tangible book value per share1.65
More ▼

Balance sheet in EURView more

Maat Pharma SA appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.26% of the market capitalization can be attributed to its 24.28m and debt could be paid in full if management chose.
Current ratio2.78
Quick ratio2.76
Total debt/total equity0.6877
Total debt/total capital0.4075
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.